DOT1L Recombinant Monoclonal Antibody

Code CSB-RA238318A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: Hela whole cell lysate, HL60 whole cell lysate, K562 whole cell lysate, SH-SY5Y whole cell lysate, U251 whole cell lysate, PC-3 whole cell lysate
    All lanes: DOT1L antibody at 1:1500
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 165, 185 kDa
    Observed band size: 185 kDa
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
DOT1L
Alternative Names
Histone-lysine N-methyltransferase, H3 lysine-79 specific (EC 2.1.1.43) (DOT1-like protein) (Histone H3-K79 methyltransferase) (H3-K79-HMTase) (Lysine N-methyltransferase 4), DOT1L, KIAA1814 KMT4
Species Reactivity
Human
Immunogen
A synthesized peptide derived from human KMT4 / Dot1L
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
3B6
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CUSABIO's product CSB-RA238318A0HU is prepared using protein and DNA recombinant technology. Initially, mice were immunized with a synthetic peptide from human DOT1L, and after a specific period, the spleen was removed aseptically. The RNA from the spleen cells was isolated, and the cDNA was generated through reverse transcription. The DOT1L antibody gene was amplified via PCR using this cDNA as a template. The obtained gene was inserted into a vector, which was then transfected into host cells for culturing. The DOT1L recombinant monoclonal antibody was purified from the cell culture supernatant using affinity chromatography and has been validated for use in ELISA and WB experiments to detect human DOT1L protein.

The DOT1L protein is specifically involved in the methylation of H3K79 on nucleosomes that contain histone H2B ubiquitinated at lysine 120 (H2Bub1). This modification is associated with the elongation phase of transcription, transcriptional activation, DNA repair, and maintenance of chromatin structure. The activity of DOT1L is thought to contribute to the proper regulation of gene expression during development and differentiation. Mutations in the DOT1L gene have been associated with certain types of leukemia.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Histone methyltransferase. Methylates 'Lys-79' of histone H3. Nucleosomes are preferred as substrate compared to free histones. Binds to DNA.
Gene References into Functions
  1. Each C-Nap1 ring at the proximal end of the two centrioles organizes a rootletin ring and, in addition, multiple rootletin/CEP68 fibers. PMID: 29463719
  2. Gene and protein expression of DOT1L was increased in synovial tissues of both osteoarthritis and rheumatoid arthritis patients. PMID: 29234911
  3. human mammary epithelial cells reprogramming is dependent on gene silencing by the DNA methyltransferase DNMT3A and loss of histone transcriptional marks following downregulation of the methyltransferase DOT1L. PMID: 28781076
  4. this study shows that Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma PMID: 27713173
  5. facilitates DNA damage repair; plays a protective role in ultraviolet radiation-induced melanomagenesis PMID: 29343685
  6. DOT1L cooperates with transcription factor ETS-1 to stimulate the expression of VEGFR2, thereby activating ERK1/2 and AKT signaling pathways and promoting angiogenesis. PMID: 27626484
  7. findings demonstrate that DOT1L over-expression has important clinical significance in ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 and CCND3 through H3K79 methylation PMID: 28114995
  8. MLL-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L. PMID: 28076791
  9. our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. PMID: 28209620
  10. These results reveal a cooperative transcriptional activation mechanism of AEP and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL fusion-AF4 complex and DOT1L for more effective treatment of MLL-rearranged leukemia. PMID: 28394257
  11. this indicates that DOT1L function, like MLL, does not completely rely on its methyltransferase activity. Nevertheless, the small molecule DOT1L inhibition is sufficient to block the proliferation of MLL fusion-induced leukemia cells of murine and human origin PMID: 26923329
  12. DOT1L may play a critical role in DNMT3A-mutant leukemia. PMID: 27335278
  13. DOT1L, via dimethylated histone H3 K79, facilitates histone H4 acetylation, which in turn regulates the binding of BRD4 to chromatin in acute lymphoblastic leukemia. PMID: 27294782
  14. study demonstrates the development of potent DOT1L inhibitors with novel scaffolds PMID: 26914852
  15. these findings strongly support the contention that histone methyltransferase, DOT1L-associated epigenetic changes induced by HA play pivotal roles in miR-10 production leading to up-regulation of RhoGTPase and survival proteins. PMID: 27002147
  16. Report drug formulation/delivery of DOT1L inhibitor pinometostat in leukemia. PMID: 26385168
  17. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. PMID: 26927674
  18. These data converge on a possible mechanism for hDot1L stimulation in which histone H2B physically 'corrals' the enzyme into a productive binding orientation. PMID: 26830124
  19. expression associated with poorer survival and aggressiveness of breast cancers PMID: 26199140
  20. analysis of a functional hotspot on ubiquitin that is required for the stimulation of human Dot1 PMID: 26240340
  21. Three candidate variants were identified: p.Glu1313Lys in Insulin receptor (INSR), p.Arg81Pro in F-box protein 24 (FBXO24) and p.Pro1146Leu in DOT1-like histone H3K79 methyltransferase PMID: 25576241
  22. The graded reduction of the DOT1L interaction with MLL-AF9 results in differential loss of H3K79me2 and me3 at MLL-AF9 target genes. PMID: 25921540
  23. The PZP domain of AF10 senses unmodified H3K27 to regulate DOT1L-mediated methylation of H3K79. PMID: 26439302
  24. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. PMID: 26118503
  25. A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese PMID: 24916648
  26. DOT1L rs12982744 G to C change and variant C genotype may contribute to knee OA risk in a Chinese Han population. PMID: 25005768
  27. inhibition of DOT1L, in combination with DNA damaging chemotherapy, represents a promising approach to improving outcomes for MLL-rearranged leukemia. PMID: 24858818
  28. Studies identified the evolutionarily conserved Af9 YEATS domain as a novel acetyllysine-binding module and established a direct link between histone acetylation and DOT1L-mediated H3K79 methylation in transcription control. PMID: 25417107
  29. Results provide evidence that transformation driven by MLL fusions as well as the recurrent AML-associated NUP98-NSD1 fusion oncogene is critically dependent on the ability of AF10 to stimulate DOT1L activity. PMID: 25464900
  30. Establishing the precise function of DOT1L in normal adult hematopoiesis and understanding its mode of action will aid in our understanding of the use of DOT1L as a therapeutic target in MLL-rearranged leukemia. PMID: 24854991
  31. DOT1L Regulates IL-22 Dependent Colon Cancer Stemness via H3K79 Methylation PMID: 24816405
  32. PITX2 forms complex with histone H3 lysine 4 (H3K4) methyltransferase. PITX2 complex methylates H3K4. PMID: 24486544
  33. Functional studies show that the mapped AF9/ENL interacting site is essential for immortalization by MLL-AF9, indicating that DOT1L interaction with MLL-AF9 and its recruitment are required for transformation by MLL-AF9. PMID: 23996074
  34. In male subjects, the rs12982744 polymorphism in DOT1L is associated with hip osteoarthritis. PMID: 23505243
  35. a functional interaction between hDOT1L and RNAPII targets hDOT1L and subsequent H3K79 methylations to actively transcribed genes. PMID: 23012353
  36. Data show that histone monoubiquitylation H2Aub did not influence histone methyltransferase Dot1L activity. PMID: 22619169
  37. These data are a further step to better understand the role of Wnt-signaling during chondrogenesis and cartilage homeostasis. DOT1L may represent a therapeutic target for osteoarthritis. PMID: 22566624
  38. These findings identify a novel role for Bat3 in regulating DOT1L function, which plays a critical role in DNA damage response. PMID: 22373577
  39. down-regulation of DOT1L-mediated H3K79 methylation disturbs proliferation of human cells PMID: 22190683
  40. a novel STAT1-DOT1L interaction that is required for the regulation JAK-STAT-inducible gene expression PMID: 22002246
  41. These data point to DOT1L as a potential therapeutic target in MLL-rearranged leukemia. PMID: 21741597
  42. This permitted structure-activity studies of ubiquitylated mononucleosomes that revealed plasticity in the mechanism of hDot1L stimulation and identified surfaces of ubiquitin important for activation. PMID: 20208522
  43. study describes for the first time the components of DotCom and links the specific regulation of H3K79 trimethylation by Dot1 and its associated factors to the Wnt/Wingless signaling pathway PMID: 20203130
  44. titration of the level of ubiquitylated histone H2B within the nucleosome revealed a 1:1 stoichiometry of Dot1L activation. PMID: 19799466
  45. mistargeting of hDOT1L to Hoxa9 plays an important role in MLL-AF10-mediated leukemogenesis PMID: 15851025
  46. Altered phosphorylation of histone-H3 is associated with hepatocarcinogenesis PMID: 17094487
  47. Identification of ENL-associated proteins by mass spectrometry revealed enzymes with a known role in transcriptional elongation: pTEFb and DOT1L. PMID: 17855633
  48. suggesting a widespread mechanism for parallel or sequential recruitment of DOT1L and MLL to genes in their normal "on" state PMID: 18285465
  49. demonstration, using chemically ubiquitylated H2B, of a direct stimulation of hDot1L-mediated intranucleosomal methylation of H3 K79 PMID: 18449190
  50. the CALM-AF10 fusion protein can also greatly reduce global H3K79 methylation in both human and murine leukemic cells by disrupting the AF10-mediated association of hDOT1L with chromatin PMID: 19443658

Show More

Hide All

Subcellular Location
Nucleus.
Protein Families
Class I-like SAM-binding methyltransferase superfamily, DOT1 family
Database Links

HGNC: 24948

OMIM: 607375

KEGG: hsa:84444

STRING: 9606.ENSP00000381657

UniGene: Hs.713641

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*